Why Ionis Pharmaceuticals, Inc. (IONS) Stock Fell 8.1% on Sep 15, 2026
The clearest new catalyst: Guggenheim price-target cut.
Why did IONS stock fall?
Ionis Pharmaceuticals fell 8.1% on September 15, 2026, to $47.25, hitting a new 52-week low as Guggenheim cut its price target from $89 to $80 citing weakened long-term sales outlook for the company's commercial portfolio. The decline extended investor losses from two recent clinical setbacks: pelacarsen's Phase 3 failure (September 5) and eplontersen's earlier July primary-endpoint miss, both of which forced analysts to strip milestone and royalty expectations from financial models. Broader healthcare sector weakness added to selling pressure.
- Guggenheim price-target cut: Guggenheim lowered its 12-month price target from $89 to $80, citing growing caution regarding long-term sales outlook for Ionis' commercial portfolio, triggering direct institutional selling pressure.
- Pelacarsen Phase 3 failure (September 5): The cardiovascular drug partnered with Novartis missed its primary endpoint in a Phase 3 trial, forcing multiple research firms to remove milestone and royalty expectations from long-term financial models.
- Eplontersen Phase 3 setback (July): Ionis' other major heart-disease candidate failed its primary endpoints in July, compounding investor concerns about the pipeline and contributing to analyst downgrades.
- Broader healthcare sector weakness: All major U.S. stock indices closed lower on September 15, with aggressive selling in high-risk biotech and healthcare sectors adding to downward pressure.
Initial detection
BestStocks first flagged IONS intraday on Sep 15, 2026; this analysis was finalized after the close using the confirmed −8.1% session move and additional catalyst research.
Show the initial intraday note
Ionis Pharmaceuticals fell 6.75% to $47.97, extending losses driven by recent Phase 3 trial disappointment for pelacarsen (partnered with Novartis) that missed its primary endpoint, compounded by analyst price target cuts from firms including Guggenheim (down to $80) and Barclays following pipeline setbacks earlier in the summer. Volume ran 1.65x normal for this point in the session, reflecting elevated trading activity amid the negative catalyst.
What to watch next: Ionis earnings scheduled for November 4, 2026 (consensus EPS estimate: −$1.21); monitor for further analyst commentary on trial implications and commercial launch timelines.
Frequently asked questions
Why did Ionis Pharmaceuticals, Inc. (IONS) stock fall on Sep 15, 2026?
Ionis Pharmaceuticals fell 8.1% on September 15, 2026, to $47.25, hitting a new 52-week low as Guggenheim cut its price target from $89 to $80 citing weakened long-term sales outlook for the company's commercial portfolio. The decline extended investor losses from two recent clinical setbacks: pelacarsen's Phase 3 failure (September 5) and eplontersen's earlier July primary-endpoint miss, both of which forced analysts to strip milestone and royalty expectations from financial models. Broader healthcare sector weakness added to selling pressure.
How much did IONS stock fall on Sep 15, 2026?
IONS fell 8.1% during the Sep 15, 2026 trading session.
What were the main drivers behind IONS's move?
Guggenheim price-target cut; Pelacarsen Phase 3 failure (September 5); Eplontersen Phase 3 setback (July); Broader healthcare sector weakness.